651P Impact of abiraterone acetate plus prednisone (AAP) in patients with castration-sensitive prostate cancer (mCSPC) and visceral metastases: Subgroup analyses of the LATITUDE study

MLA

Giulia Baciarello, et al. “651P Impact of Abiraterone Acetate plus Prednisone (AAP) in Patients with Castration-Sensitive Prostate Cancer (MCSPC) and Visceral Metastases: Subgroup Analyses of the LATITUDE Study.” Annals of Oncology, vol. 31, Sept. 2020, pp. S530–31. EBSCOhost, https://doi.org/10.1016/j.annonc.2020.08.910.

APA

Giulia Baciarello, Mustafa Ozguroglu, Suneel Mundle, Peter Hu, U. Richarz, G. Leitz, Kim N. Chi, & Karim Fizazi. (2020). 651P Impact of abiraterone acetate plus prednisone (AAP) in patients with castration-sensitive prostate cancer (mCSPC) and visceral metastases: Subgroup analyses of the LATITUDE study. Annals of Oncology, 31, S530–S531. https://doi.org/10.1016/j.annonc.2020.08.910

Chicago

Giulia Baciarello, Mustafa Ozguroglu, Suneel Mundle, Peter Hu, U. Richarz, G. Leitz, Kim N. Chi, and Karim Fizazi. 2020. “651P Impact of Abiraterone Acetate plus Prednisone (AAP) in Patients with Castration-Sensitive Prostate Cancer (MCSPC) and Visceral Metastases: Subgroup Analyses of the LATITUDE Study.” Annals of Oncology 31 (September): S530–31. doi:10.1016/j.annonc.2020.08.910.